Live Status Check

NCT02926690 Recruiting Status

Real-time enrollment status for this relapsed/refractory locally advanced or metastatic breast cancer and triple negative breast cancer clinical trial

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Checked: July 13, 2026 at 8:48 AM UTC

NCT02926690 Status Summary

NCT NumberNCT02926690
Recruiting StatusRecruiting
ConditionRelapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
PhaseClinical Trial
Target Enrollment70 participants
Active Locations8 sites in the US
SponsorOncoTherapy Science, Inc.
Last Updated on CT.govFebruary 25, 2026 (Feb 25, 2026)

About NCT02926690 Enrollment Status

As of July 13, 2026: Clinical trial NCT02926690 is currently recruiting participants. This clinical trial study for relapsed/refractory locally advanced or metastatic breast cancer and triple negative breast cancer is actively seeking new participants at 8 locations across the United States. The study is sponsored by OncoTherapy Science, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.

Frequently Asked Questions About NCT02926690

Is NCT02926690 still recruiting?

Yes, NCT02926690 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.

Where is NCT02926690 recruiting?

This trial is recruiting at 8 locations in the United States. View all available locations on the full study page.

How do I enroll in NCT02926690?

Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.

When was NCT02926690 status last updated?

The official ClinicalTrials.gov record for NCT02926690 was last updated Feb 25, 2026 (February 25, 2026). HelloStudys verifies this status automatically.

Browse More Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer Trials

Ready to Apply?

Check your eligibility for this clinical trial